Swedish drug tech Biotage acquires U.S.-based PhyNexus for $21.5M

Swedavia has sold a future Comfort hotel at Stockholm Arlanda Airport to boost the hotel's competitive edge and meet growing traveler numbers.
Swedish pharma technology company Biotage snapped up U.S.-based PhyNexus in a deal valued at $21.5 million. (Thomas Fabian)

Swedish pharma technology company Biotage snapped up U.S.-based PhyNexus in a deal valued at $21.5 million.

The acquisition is expected to bolster Biotage’s presence as a separations company within the growing biomolecule arena. The company said it will now be able to provide an automation platform based on Dual flow Chromatography and patented tip technology for higher throughput purification of biomolecules such as proteins, plasmids and antibodies at the lab-scale.

“This transaction enables PhyNexus’ products to reach a larger global market through Biotage’s direct sales organization, at the same time as Biotage obtains access to customers in industries where Biotage historically has not been active,” Torben Jörgensen, Biotage’s chief executive, said in a statement. 

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

The company expects the platform has the potential to address a growing multibillion-dollar market, and that the platform will provide enhanced high-throughput workflow approaches for clinical, forensic, food and environmental testing.

Financing for the deal was conducted with a combination of newly issued shares of Biotage and cash.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.

Big Pharma AstraZeneca and academic partner the University of Oxford are tapping research services firm CCT for their COVID-19 shot tests in Arizona.